Delivery of peptide and protein drugs over the blood-brain barrier

被引:210
作者
Brasnjevic, Ivona [1 ]
Steinbusch, Harry W. M. [1 ]
Schmitz, Christoph [1 ]
Martinez-Martinez, Pilar [1 ]
机构
[1] Maastricht Univ, European Grad Sch Neurosci EURON, NL-6200 MD Maastricht, Netherlands
关键词
Blood-brain barrier; Delivery strategies; Neurodegenerative diseases; Neurotherapeutics; Peptide- and protein-drug targeting; Pharmacotherapy; Therapeutic strategies; CENTRAL-NERVOUS-SYSTEM; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES; AMYOTROPHIC-LATERAL-SCLEROSIS; GROWTH-FACTOR-I; SOLID LIPID NANOPARTICLES; AMYLOID PRECURSOR PROTEIN; VASOACTIVE-INTESTINAL-PEPTIDE; STRIATAL PROJECTION NEURONS; CARRIER-MEDIATED TRANSPORT; PLACEBO-CONTROLLED TRIAL;
D O I
10.1016/j.pneurobio.2008.12.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Peptide and protein (P/P) drugs have been identified as showing great promises for the treatment of various neurodegenerative diseases. A major challenge in this regard, however, is the delivery of P/P drugs over the blood-brain barrier (BBB). Intense research over the last 25 years has enabled a better understanding of the cellular and molecular transport mechanisms at the BBB, and several strategies for enhanced P/P drug delivery over the BBB have been developed and tested in preclinical and clinical-experimental research. Among them, technology-based approaches (comprising functionalized nanocarriers and liposomes) and pharmacological strategies (such as the use of carrier systems and chimeric peptide technology) appear to be the most promising ones. This review combines a comprehensive overview on the current understanding of the transport mechanisms at the BBB with promising selected strategies published so far that can be applied to facilitate enhanced P/P drug delivery over the BBB. (C) 2009 Published by Elsevier Ltd.
引用
收藏
页码:212 / 251
页数:40
相关论文
共 696 条
[1]   Neuropathology of dementia in Parkinson's disease: A prospective, community-based study [J].
Aarsland, D ;
Perry, R ;
Brown, A ;
Larsen, JP ;
Ballard, C .
ANNALS OF NEUROLOGY, 2005, 58 (05) :773-776
[2]   A systematic review of prevalence studies of dementia in Parkinson's disease [J].
Aarsland, D ;
Zaccai, J ;
Brayne, C .
MOVEMENT DISORDERS, 2005, 20 (10) :1255-1263
[3]   Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia [J].
Aarsland, D ;
Hutchinson, M ;
Larsen, JP .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (10) :937-941
[4]   Transporting therapeutics across the blood-brain barrier [J].
Abbott, NJ ;
Romero, IA .
MOLECULAR MEDICINE TODAY, 1996, 2 (03) :106-113
[5]   Astrocyte-endothelial interactions and blood-brain barrier permeability [J].
Abbott, NJ .
JOURNAL OF ANATOMY, 2002, 200 (06) :629-638
[6]   Inflammatory mediators and modulation of blood-brain barrier permeability [J].
Abbott, NJ .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2000, 20 (02) :131-147
[7]  
Abbruscato TJ, 1997, J NEUROCHEM, V69, P1236
[8]  
ADAMS P, 1988, AM J HUM GENET, V43, P695
[9]   Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease [J].
Adessi, C ;
Frossard, MJ ;
Boissard, C ;
Fraga, S ;
Bieler, S ;
Ruckle, T ;
Vilbois, F ;
Robinson, SM ;
Mutter, M ;
Banks, WA ;
Soto, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (16) :13905-13911
[10]   ELECTRICAL CHARGE - ITS ROLE IN THE PATHOGENESIS AND PREVENTION OF EXPERIMENTAL MEMBRANOUS NEPHROPATHY IN THE RABBIT [J].
ADLER, SG ;
WANG, H ;
WARD, HJ ;
COHEN, AH ;
BORDER, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (03) :487-499